2011 ACC VIDEO: Cost Analysis Substituting Dabigatran for Warfarin

Article

Dr. Julie Atay discusses the two main objectives of her poster which evaluated the cost analysis of substituting Dabigatran for Warfarin.

Dr. Julie Atay discusses her poster, "Cost Analysis of Substituting Dabigatran for Warfarin in an Anticoagulant Management Program," at ACC's 60th Annual Scientific Sessions. Dr. Atay provides a quick explanation about the two objectives her colleagues and she were evaluating: 1) The percentage of patients already on Warfarin who qualified to be on Dabigatran; and 2) The direct costs associated with switching patients from Warfarin to Dabigatran.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.